Abstract 5523: Adoptive cellular immunotherapy contributes to better survival for NSCLC patients: Case-control study of 395 Japanese patients with advanced NSCLC

• Published in: Cancer research (Chicago, Ill.) Vol. 71; no. 8_Supplement; p. 5523
• Main Authors: Soejima, Kenzo, Iwai, Kazuro, Umesato, Yoshimasa, Goto, Shigenori, Kudo, Shoji
• Format: Journal Article
• Language: English
• Published: 15.04.2011
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2011-5523

Abstract Adoptive cellular immunotherapy (ITx) targeting various types of carcinoma including the lung is widely used, yet the clinical effectiveness has not been evaluated in large cases of lung carcinoma. So we carried out a case-control study to investigate the effect of ITx for the treatment of advanced non-small cell lung cancer (NSCLC) patients in Japanese population. Between 2001 and 2006, 163 patients were identified as having advanced NSCLC with ECOG performance status (PS) 0/1 who underwent ITx with or without standard chemotherapy (CTx). The controls were 232 advanced NSCLC patients with PS 0/1 who had standard CTx or BSC alone. Overall survival (OS) and 1- and 2-year survival were obtained with Kaplan-Meyer survival curves and compared using log-rank and generalized Wilcoxon analysis. Multivariate analysis with Cox proportional hazard models was also performed to analyze survival. The mean age of total population was 64.8 + 10.6 years. There were 251 males and 144 females and 295 adenocarcinoma (Ad) and 74 squamous cell carcinoma (Sq) patients. The mean period and frequency of ITx was 10.2 months and 8.7 times, respectively. Median OS for CTx and ITx + CTx was 15.7 and 20.8 months, respectively. Multivariate analysis with Cox proportional hazard model showed that sex (male vs female) (HR=0.33, p<0.001) and histology (Ad vs Sq) (HR=0.14, p=0.045) were independent predictors of OS. It is revealed that ITx when administered as monotherapy was effective compared to BSC in male with Sq (HR=0.47, p=0.038) and female with Ad (HR=0.53, p=0.016). Additional effect of ITx on CTx was obtained in Ad histology, especially in female (p=0.039). The present findings suggest that ITx may contribute to better survival for advanced or metastatic NSCLC patients under certain circumstances. These results should be confirmed in large prospective clinical trials. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5523. doi:10.1158/1538-7445.AM2011-5523